Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis

Journal of Clinical Oncology

Volumn 23, Issue 5, 2005, Pages 1011-1027

  Hicklin, Daniel J ^a   Ellis, Lee M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4 BROMO 2,6 DIFLUOROBENZYLOXY) 5 [3 [4 (1 PYRROLIDINYL)BUTYL]UREIDO] 4 ISOTHIAZOLECARBOXAMIDE; 4 (4 FLUORO 2 METHYL 5 INDOLYLOXY) 6 METHOXY 7 [3 (1 PYRROLIDINYL)PROPOXY]QUINAZOLINE; 5,6,7,13 TETRAHYDRO 12 (3 HYDROXYPROPYL) 9 ISOPROPOXYMETHYLINDENO[2,1 A]PYRROLO[3,4 C]CARBAZOL 5(12H) ONE DIMETHYLGLYCINE ESTER; 6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; AG 13925; ANTINEOPLASTIC AGENT; AXITINIB; BAY 93 4006; BEVACIZUMAB; CDP 791; CETUXIMAB; CYTOTOXIC AGENT; GW 786024; IMC 1121 B; IMC 1121B; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY; N (3,3 DIMETHYL 6 INDOLINYL) 2 (4 PYRIDINYLMETHYLAMINO)NICOTINAMIDE; NEUROPILIN 1; NEUROPILIN 2; PROTEIN TYROSINE KINASE INHIBITOR; SUNITINIB; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3; VATALANIB; ANGIOGENESIS INHIBITOR; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; BINDING AFFINITY; CANCER; CANCER RESEARCH; CELL GROWTH; CELL MEMBRANE PERMEABILITY; CELL MIGRATION; CELL SURVIVAL; CHEMOTHERAPY; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; GENE EXPRESSION; HUMAN; LIGAND BINDING; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN FUNCTION; RECEPTOR BINDING; REVIEW; TUMOR GROWTH; TUMOR SUPPRESSOR GENE; ANIMAL; DRUG ANTAGONISM; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PATHOPHYSIOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 14644440555     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.06.081     Document Type: Review

References (240)

1. Folkman J: Tumor angiogenesis: therapeutic implications. N Engl J Med 285:1182-1186, 1971
2. Folkman J: What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82:4-6, 1990
3. Fidler IJ, Ellis LM: The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 79:185-188, 1994
4. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 100:57-70, 2000
5. Brown LF, Detmar M, Claffey K, et al: Vascular permeability factor/vascular endothelial growth factor: a multifunctional angiogenic cytokine. EXS 79:233-269, 1997
6. Dvorak HF, Brown LF, Detmar M, et al: Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 146:1029-1039, 1995
7. Reinmuth N, Parikh AA, Ahmad SA, et al: Biology of angiogenesis in tumors of the gastrointestinal tract. Microsc Res Tech 60: 199-207, 2003
8. Rafii S, Lyden D, Benezra R, et al: Vascular and haematopoietic stem cells: Novel targets for anti-angiogenesis therapy. Nat Rev Cancer 2:826-835, 2002
9. Zebrowski BK, Yano S, Liu W, et al: Vascular endothelial growth factor levels and induction of permeability in malignant pleural effusions. Clin Cancer Res 5:3364-3368, 1999
10. Zebrowski BK, Liu W, Ramirez K, et al: Markedly elevated levels of vascular endothelial growth factor in malignant ascites. Ann Surg Oncol 6:373-378, 1999
11. Lee JC, Chow NH, Wang ST, et al: Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients. Eur J Cancer 36:748-753, 2000
12. Takahashi Y, Kitadai Y, Bucana CD, et al: Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res 55:3964-3968, 1995
13. Takahashi Y, Cleary KR, Mai M, et al: Significance of vessel count and vascular endothelial growth factor and its receptor (KDR) in intestinal-type gastric cancer. Clin Cancer Res 2:1679-1684, 1996
14. Maeda K, Chung YS, Ogawa Y, et al: Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer 77:858-863, 1996
15. Fujimoto K, Hosotani R, Wada M, et al: Expression of two angiogenic factors, vascular endothelial growth factor and platelet-derived endothelial cell growth factor in human pancreatic cancer, and its relationship to angiogenesis. Eur J Cancer 34:1439-1447, 1998
16. Ikeda N, Adachi M, Taki T, et al. Prognostic significance of angiogenesis in human pancreatic cancer. Br J Cancer 79:1553-1563, 1999
17. Berns EM, Klijn JG, Look MP, et al: Combined vascular endothelial growth factor and TP53 status predicts poor response to tamoxifen therapy in estrogen receptor-positive advanced breast cancer. Clin Cancer Res 9:1253-1258, 2003
18. Manders P, Beex LV, Tjan-Heijnen VC, et al: The prognostic value of vascular endothelial growth factor in 574 node-negative breast cancer patients who did not receive adjuvant systemic therapy. Br J Cancer 87:772-778, 2002
19. George DJ, Halabi S, Shepard TF, et al: Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. Clin Cancer Res 7:1932-1936, 2001
20. Fontanini G, Lucchi M, Vignati S, et al: Angiogenesis as a prognostic indicator of survival in non-small-cell lung carcinoma: A prospective study. J Natl Cancer Inst 89:881-886, 1997
21. Gorski DH, Leal AD, Goydos JS: Differential expression of vascular endothelial growth factor-A isoforms at different stages of melanoma progression. J Am Coll Surg 197:408-418, 2003
22. Ferrara N, Gerber HP, LeCouter J: The biology of VEGF and its receptors. Nat Med 9:669-676, 2003
23. Houck K: The vascular endothelial growth factor family: Identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol 5:1806-1814, 1991
24. Tischer E, Mitchell R, Hartman T, et al: The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem 266:11947-11954, 1991
25. Senger DR, Galli SJ, Dvorak AM, et al: Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219:983-985, 1983
26. Leung DW, Cachianes G, Kuang WJ, et al: Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246:1306-1309, 1989
27. Neufeld G, Cohen T, Gengrinovitch S, et al: Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 13:9-22, 1999
28. Dvorak HF: Vascular permeability factor/ vascular endothelial growth factor: A critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 20:4368-4380, 2002
29. Keyt BA, Berleau LT, Nguyen HV, et al: The carboxyl-terminal domain (111-165) of vascular endothelial growth factor is critical for its mitogenic potency. J Biol Chem 271:7788-7795, 1996
30. Park JE, Keller GA, Ferrara N: The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol Biol Cell 4:1317-1326, 1993
31. McColl BK, Baldwin ME, Roufail S, et al: Plasmin activates the lymphangiogenic growth factors VEGF-C and VEGF-D. J Exp Med 198: 863-868, 2003
32. Bergers G, Brekken R, McMahon G, et al: Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2:737-744, 2000
33. Ferrara N: Molecular and biological properties of vascular endothelial growth factor. J Mol Med 77:527-543, 1999
34. Ferrara N: Vascular endothelial growth factor and the regulation of angiogenesis. Recent Prog Horm Res 55:15-36, 2000
35. Cross MJ, Dixelius J, Matsumoto T, et al: VEGF receptor signal transduction. Trends Biochem Sci 28:488-494, 2003
36. Jakeman LB, Armanini M, Phillips HS, et al: Developmental expression of binding sites and messenger ribonucleic acid for vascular endothelial growth factor suggests a role for this protein in vasculogenesis and angiogenesis, Endocrinology 133:848-659, 1993
37. Shweiki D, Itin A, Neufeld G, et al: Patterns of expression of vascular endothelial growth factor (VEGF) and VEGF receptors in mice suggest a role in hormonally regulated angiogenesis. J Clin Invest 91:2235-2243, 1993
38. Carmeliet P, Ferreira V, Breier G, et al: Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380:435-439, 1996
39. Ferrara N: Vascular endothelial growth factor. Eur J Cancer 32A:2413-2422, 1996
40. Brown LF, Yeo KT, Berse B, et al: Expression of vascular permeability factor (vascular endothelial growth factor) by epidermal keratinocytes during wound healing. J Exp Med 176:1375-1379, 1992
41. Carmeliet P, Moons L, Luttun A, et al: Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 7:575-583, 2001
42. Karkkainen MJ, Haiko P, Sainio K, et al: Vacular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins. Nat Immunol 5:74-80, 2004
43. Jeltsch M, Kaipainen A, Joukov V, et al: Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science 276:1423-1425, 1997
44. Veikkola T, Jussila L, Makinen T, et al: Signaling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice. EMBO J 20:1223-1231, 2001
45. Ogawa S, Oku A, Sawano A, et al: A novel type of vascular endothelial growth factor, VEGF-E (NZ-7 VEGF), preferentially utilizes KDR/Flk-1 receptor and carries a potent mitotic activity without heparin-binding domain. J Biol Chem 273:31273-31282, 1998
46. Shibuya M, Yamaguchi S, Yamane A, et al: Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase (flt) closely related to the fms family. Oncogene 5:519-524, 1990
47. Terman B: Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem Biophys Res Commun 187:1579-1586, 1992
48. Matthews W, Jordan CT, Gavin M, et al: A receptor tyrosine kinase cDNA isolated from a population of enriched primitive hematopoietic cells and exhibiting close genetic linkage to c-kit. Proc Natl Acad Sci U S A 88:9026-9030, 1991
49. Terman B: Identification of a new endothelial cell growth factor receptor tyrosine kinase. Oncogene 6:1677-1683, 1991
50. Kaipainen A, Korhonen J, Mustonen T, et al: Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proc Natl Acad Sci U S A 92:3566-3570, 1995
51. Paavonen K, Puolakkainen P, Jussila L, et al: Vascular endothelial growth factor receptor-3 in lymphangiogenesis in wound healing. Am J Pathol 156:1499-1504, 2000
52. Park J, Chen H, Winer J, et al: Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/ KDR. J Biol Chem 269:25646-25654, 1994
53. Olofsson B, Korpelainen E, Pepper MS, et al: Vascular endothelial growth factor B (VEGFB) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells. Proc Natl Acad Sci U S A 95:11709-11714, 1998
54. Silvestre JS, Tamarat R, Ebrahimian TG, et al: Vascular endothelial growth factor-B promotes in vivo angiogenesis. Circ Res 93:114-123, 2003
55. Cao Y, Chen H, Zhou L, et al: Heterodimers of placenta growth factor/vascular endothelial growth factor. J Biol Chem 271:3154-3162, 1996
56. DiSalvo J, Conn G, Trivedi PG, et al: Purification and characterization of a naturally occurring vascular endothelial growth factor heterodimer. J Biol Chem 270:7717-7723, 1995
57. Shibuya M: Vascular endothelial growth factor receptor-2: its unique signaling and specific ligand, VEGF-E. Cancer Sei 94:751-756, 2003
58. Achen MG, Jeltsch M, Kukk E, et al: Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc Natl Acad Sci U S A 95:548-553, 1998
59. Joukov V, Pajusola K, Kaipainen A, et al: A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J 15:290-298, 1996
60. de Vries C, Escobedo JA, Ueno H, et al: The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 255:989-991, 1992
61. Fong GH, Rossant J, Gertsenstein M, et al: Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 376:66-70, 1995
62. Hiratsuka S, Minowa O, Kuno J, et al: Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. Proc Natl Acad Sci U S A. 95:9349-9354, 1998
63. Dunk C, Ahmed A: Vascular endothelial growth factor receptor-2-mediated mitogenesis is negatively regulated by vascular endothelial growth factor receptor-1 in tumor epithelial cells. Am J Pathol 158:265-273, 2001
64. Waltenberger J, Claesson-Welsh L, Siegbahn A, et al: Different signal transduction properties of KDR and Flt-1, two receptors for vascular endothelial growth factor. J Biol Chem 269:26988-26995, 1994
65. Gille H, Kowalski J, Yu L, et al: A repressor sequence in the juxtamembrane domain of Flt-1 (VEGFR-1) constitutively inhibits vascular endothelial growth factor-dependent phosphatidylinositol 3′-kinase activation and endothelial cell migration. EMBO J 19:4064-4073, 2000
66. Zeng H, Dvorak HF, Mukhopadhyay D: Vascular permeability factor (VPF)/vascular endothelial growth factor (VEGF) receptor-1 down-modulates VPF/VEGF receptor-2-mediated endothelial cell proliferation, but not migration. through phosphatidylinositol 3-kinase-dependent pathways. J Biol Chem 276:26969-26979, 2001
67. Barleon B, Sozzani S, Zhou D, et al: Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood 87:3336-3343, 1996
68. Clauss M, Weich H, Breier G, et al: The vascular endothelial growth factor receptor Flt-1 mediates biological activities. Implications for a functional role of placenta growth factor in monocyte activation and chemotaxis. J Biol Chem 271:17629-17634, 1996
69. Lyden D, Hattori K, Dias S, et al: Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 7:1194-1201, 2001
70. Chen WS, Kitson RP, Goldfarb RH: Modulation of human NK cell lines by vascular endothelial growth factor and receptor VEGFR-1 (FLT-1). In Vivo 16:439-445, 2002
71. LeCouter J, Moritz DR, Li B, et al: Angiogenesis-independent endothelial protection of liver: Role of VEGFR-1. Science 299:890-893, 2003
72. Autiero M, Waltenberger J, Communi D, et al: Role of PIGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. Nat Med 9:936-943, 2003
73. Hiratsuka S, Maru Y, Okada A, et al: Involvement of Flt-1 tyrosine kinase (vascular endothelial growth factor receptor-1) in pathological angiogenesis. Cancer Res 61:1207-1213, 2001
74. Kendall R, Thomas K: Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci U S A 90:10705-10709, 1993
75. Banks R, Forbes M, Searles J, et al: Evidence for the existence of a novel pregnancy-associated soluble variant of the vascular endothelial growth factor receptor, Flt-1. Mol Hum Reprod 4:377-386, 1998
76. Krussel J, Casan E, Raga F, et al. Expression of mRNA for vascular endothelial growth factor transmembranous receptors Flt1 and KDR, and the soluble receptor sflt in cycling human endometrium. Mol Hum Reprod 5: 452-458, 1999
77. Lamszus K, Ulbricht U, Matschke J, et al: Levels of soluble vascular endothelial growth factor (VEGF) receptor 1 in astrocytic tumors and its relation to malignancy, vascularity, and VEGF-A. Clin Cancer Res 9:1399-1405, 2003
78. Toi M, Bando H, Ogawa T, et al: Significance of vascular endothelial growth factor (VEGF)/soluble VEGF receptor-1 relationship in breast cancer. Int J Cancer 98:14-18, 2002
79. Millauer B, Wizigmann-Voos S, Schnurch H, et al: High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell 72:835-846, 1993
80. Shabby F: Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice, Nature 376:62-66, 1995
81. Veikkola T, Karkkainen M, Claesson-Welsh L, et al: Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res 60:203-212, 2000
82. Abedi H, Zachary I: Vascular endothelial growth factor stimulates tyrosine phosphorylation and recruitment to new focal adhesions of focal adhesion kinase and paxillin in endothelial cells. J Biol Chem 272:15442-15451, 1997
83. Pajusola K, Aprelikova O, Armstrong E, et al: Two human FLT4 receptor tyrosine kinase isoforms with distinct carboxy terminal tails are produced by alternative processing of primary transcripts. Oncogene 8:2931-2937, 1993
84. Galland F, Karamysheva A, Pebusque MJ, et al: The FLT4 gene encodes a transmembrane tyrosine kinase related to the vascular endothelial growth factor receptor. Oncogene 8:1233-1240, 1993
85. Dumont DJ, Jussila L, Taipale J, et al: Cardiovascular failure in mouse embryos deficient in VEGF receptor-3. Science 282:946-949, 1998
86. Irrthum A, Karkkainen MJ, Devriendt K, et al: Congenital hereditary lymphedema caused by a mutation that inactivates VEGFR3 tyrosine kinase. Am J Hum Genet 67:295-301, 2000
87. Karkkainen MJ, Ferrell RE, Lawrence EC, et al: Missense mutations interfere with VEGFR-3 signaling in primary lymphoedema. Nat Genet 25:153-159, 2000
88. Matsumura K, Hirashima M, Ogawa M, et al: Modulation of VEGFR-2-mediated endothelial-cell activity by VEGF-C/VEGFR-3. Blood 101:1367-1374, 2003
89. Achen MG, Williams RA, Minekus MP, et al: Localization of vascular endothelial growth factor-D in malignant melanoma suggests a role in tumour angiogenesis. J Pathol 193:147-154, 2001
90. Valtola R, Salven P, Heikkila P, et al: VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer. Am J Pathol 154:1381-1390, 1999
91. Pepper MS, Tille JC, Nisato R, et al: Lymphangiogenesis and tumor metastasis. Cell Tissue Res 314:167-177, 2003
92. Mandriota SJ, Jussila L, Jeltsch M, et al: Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. EMBO J 20:672-682, 2001
93. Stacker SA, Caesar C, Baldwin ME, et al: VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat Med 7:186-191, 2001
94. He Y, Kozaki K, Karpanen T, et al: Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling. J Natl Cancer Inst 94:819-825, 2002
95. Miao HQ, Klagsbrun M: Neuropilin is a mediator of angiogenesis. Cancer Metastasis Rev 19:29-37, 2000
96. Fuh G, Garcia C, de Vos A: The interaction of neuropilin-1 with vascular endothelial growth factor and its receptor Flt-1. J Biol Chem 275:26690-26695, 2000
97. Takahashi T, Nakamura F, Jin Z, et al: Semaphorins A and E act as antagonists of neuropilin-1 and agonists of neuropilin-2 receptors. Nat Neurosci 1:487-493, 1998
98. Soker S, Takashima S, Miao HQ, et al: Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 92:735-745, 1998
99. Soker S, Fidder H, Neufeld G, et al: Characterization of novel vascular endothelial growth factor (VEGF) receptors on tumor cells that bind VEGF165 via its exon 7-encoded domain. J Biol Chem 271:5761-5767, 1996
100. Soker S: Neuropilin in the midst of cell migration and retraction. Int J Biochem Cell Biol 33:433-437, 2001
101. Karkkainen MJ, Saaristo A, Jussila L, et al: A model for gene therapy of human hereditary lymphedema. Proc Natl Acad Sci U S A 98:12677-12682, 2001
102. Soker S, Gollamudi-Payne S, Fidder H, et al: Inhibition of vascular endothelial growth factor (VEGF)-induced endothelial cell proliferation by a peptide corresponding to the exon 7-encoded domain of VEGF165. J Biol Chem 272:31582-31588, 1997
103. Makinen T, Olofsson B, Karpanen T, et al: Differential binding of vascular endothelial growth factor b splice and proteolytic isoforms to neuropilin-1. J Biol Chem 274:21217-21222, 1999
104. Migdal M, Huppertz B, Tessler S, et al: Neuropilin-1 is a placenta growth factor-2 receptor. J Biol Chem 273:22272-22278, 1998
105. Gluzman-Poltorak Z, Cohen T, Herzog Y, et al: neuropilin-2 and neuropilin-1 are receptors for the 165-amino acid form of vascular endothelial growth factor (VEGF) and of placenta growth factor-2, but only neuropilin-2 functions as a receptor for the 145-amino acid form of VEGF. J Biol Chem 275:18040-18045, 2000
106. Kawasaki T, Kitsukawa T, Bekku Y, et al: A requirement for neuropilin-1 in embryonic vessel formation. Development 126:4895-4902, 1999
107. Kitsukawa T, Shimono A, Kawakami A, et al: Overexpression of a membrane protein, neuropilin, in chimeric mice causes anomalies in the cardiovascular system, nervous system and limbs. Development 121:4309-4318, 1995
108. Takashima S, Kitakaze M, Asakura M, et al: Targeting of both mouse neuropilin-1 and neuropilin-2 genes severely impairs developmental yolk sac and embryonic angiogenesis. Proc Natl Acad Sci U S A 99:3657-3662, 2002
109. Yuan L, Moyon D, Pardanaud L, et al: Abnormal lymphatic vessel development in neuropilin 2 mutant mice. Development 129: 4797-4806, 2002
110. Gagnon ML, Bielenberg DR, Gechtman Z, et al: Identification of a natural soluble neuropilin-1 that binds vascular endothelial growth factor: In vivo expression and antitumor activity. Proc Natl Acad Sci U S A 97:2573-2578, 2000
111. Yoshiji H, Kuriyama S, Hicklin DJ, et al: The vascular endothelial growth factor receptor KDR/ Flk-1 is a major regulator of malignant ascites formation in the mouse hepatocellular carcinoma model. Hepatology 33:841-847, 2001
112. Yuan F, Chen Y, Dellian M, et al: Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci U S A 93:14765-14770, 1996
113. Shaheen RM, Ahmad SA, Liu W, et al: Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors. Br J Cancer 85:584-589, 2001
114. Gerber HP, Hillan KJ, Ryan AM, et al: VEGF is required for growth and survival in neonatal mice. Development 126:1149-1159, 1999
115. Zachary I, Gliki G: Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family. Cardiovasc Res 49:568-581, 2001
116. Zachary I: Signaling mechanisms mediating vascular protective actions of vascular endothelial growth factor. Am J Physiol Cell Physiol 280:C1375-C1386, 2001
117. Zhang H, Wu J, Meng L, et al: Expression of vascular endothelial growth factor and its receptors KDR and Flt-1 in gastric cancer cells. World J Gastroenterol 8:994-998, 2002
118. Ferrara N: VEGF: An update on biological and therapeutic aspects. Curr Opin Biotechnol 11:617-624, 2000
119. Bates DO, Harper SJ: Regulation of vascular permeability by vascular endothelial growth factors. Vascul Pharmacol 39:225-237, 2002
120. Zachary I: Signaling mechanisms mediating vascular protective actions of vascular endothelial growth factor. Am J Physiol Cell Physiol 280:C1375-C1386, 2001
121. Eliceiri BP, Cheresh DA: Adhesion events in angiogenesis. Curr Opin Cell Biol 13:563-568, 2001
122. Eliceiri BP, Cheresh DA: The role of alphav integrins during angiogenesis: insights into potential mechanisms of action and clinical development. J Clin Invest 103:1227-1230, 1999
123. Brooks PC, Montgomery AM, Rosenfeld M, et al: Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 79:1157-1164, 1994
124. Alon T, Hemo I, Itin A, et al: Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med 1:1024-1028, 1995
125. Gerber H, McMurtrey A, Kowalski J, et al: Vascular endothelial growth factor regulates endothelial cell survival by the Pl3-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem 273:30336-30343, 1998
126. Gerber HP, Dixit V, Ferrara N: Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells. J Biol Chem 273: 13313-13316, 1998
127. Thakker GD, Hajjar DP, Muller WA, et al: The role of phosphatidylinositol 3-kinase in vascular endothelial growth factor signaling. J Biol Chem 274:10002-10007, 1999
128. Benjamin LE, Golijanin D, Itin A, et al: Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 103:159-165, 1999
129. Meadows KN, Bryant P, Pumiglia K: Vascular endothelial growth factor induction of the angiogenic phenotype requires Ras activation. J Biol Chem 276:49289-49298, 2001
130. Kumar R, Yoneda J, Bucana CD, et al: Regulation of distinct steps of angiogenesis by different angiogenic molecules. Int J Oncol 12:749-757, 1998
131. Choong PF, Nadesapillai AP: Urokinase plasminogen activator system: A multifunctional role in tumor progression and metastasis. Clin Orthop:S46-58, 2003 (suppl 415)
132. Ferrara N, Davis-Smyth T: The biology of vascular endothelial growth factor. Endocr Rev 18:4-25, 1997
133. Rafii S, Lyden D: Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration. Nat Med 9:702-712, 2003
134. Asahara T, Murohara T, Sullivan A, et al: Isolation of putative progenitor endothelial cells for angiogenesis. Science 275:964-967, 1997
135. Luttun A, Tjwa M, Moons L, et al: Revascularization of ischemic tissues by PIGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med 8:831-840, 2002
136. Garcia-Barros M, Paris F, Cordon-Cardo C, et al: Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 300:1155-1159, 2003
137. De Palma M, Venneri MA, Roca C, et al: Targeting exogenous genes to tumor angiogenesis by transplantation of genetically modified hematopoietic stem cells. Nat Med 9:789-795, 2003
138. Gothert JR, Gustin SE, van Eekelen JM, et al: Genetically tagging endothelial cells in vivo: Bone marrow-derived cells do not contribute to tumor endothelium. Blood 104:1769-1777, 2004
139. Rajantie I, Ilmonen M, Alminaite A, et al: Adult bone marrow-derived cells recruited during angiogenesis comprise precursors for periendothelial vascular mural cells. Blood 104:2084-2086, 2004
140. Iliopoulos O, Levy AP, Jiang C, et al: Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Natl Acad Sci U S A 93:10595-10599, 1996
141. Maxwell PH, Wiesener MS, Chang GW, et al: The tumor suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399:271-275, 1999
142. Maxwell PH, Ratcliffe PJ: Oxygen sensors and angiogenesis. Semin Cell Dev Biol 13:29-37, 2002
143. Ciardiello F, Bianco R, Damiano V, et al: Antiangiogenic and antitumor activity of antiepidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. Clin Cancer Res 6:3739-3747, 2000
144. Bruns CJ, Harbison MT, Davis DW, et al: Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clin Cancer Res 6:1936-1948, 2000
145. Akagi M, Kawaguchi M, Liu W, et al: Induction of neuropilin-1 and vascular endothelial growth factor by epidermal growth factor in human gastric cancer cells. Br J Cancer 88:796-802, 2003
146. Kumar R, Yarmand-Bagheri R: The role of HER2 in angiogenesis. Semin Oncol 28:27-32, 2001
147. Yang W, Klos K, Yang Y, et al: ErbB2 overexpression correlates with increased expression of vascular endothelial growth factors A, C, and D in human breast carcinoma. Cancer 94:2855-2861, 2002
148. Eller JL, Longo SL, Hicklin DJ, et al: Activity of anti-epidermal growth factor receptor monoclonal antibody C225 against glioblastoma multiforme. Neurosurgery 51:1005-1014, 2002
149. Yano S, Muguruma H, Sone S: Non-small cell lung cancer: 1) Molecular-target therapy. Nippon Naika Gakkai Zasshi 92:318-323, 2003
150. Kedar D, Baker CH, Killion JJ, et al: Blockade of the epidermal growth factor receptor signaling inhibits angiogenesis leading to regression of human renal cell carcinoma growing orthotopically in nude mice. Clin Cancer Res 8:3592-3600, 2002
151. Reinmuth N, Fan F, Liu W, et al: Impact of insulin-like growth factor receptor-I function on angiogenesis, growth, and metastasis of colon cancer. Lab Invest 82:1377-1389, 2002
152. Reinmuth N, Liu W, Fan F, et al: Blockade of insulin-like growth factor I receptor function inhibits growth and angiogenesis of colon cancer. Clin Cancer Res 8:3259-3269, 2002
153. Akagi Y, Liu W, Zebrowski B, et al: Regulation of vascular endothelial growth factor expression in human colon cancer by insulin-like growth factor-I. Cancer Res 58:4008-4014, 1998
154. Warren RS, Yuan H, Matli MR, et al: Induction of vascular endothelial growth factor by insulin-like growth factor 1 in colorectal carcinoma. J Biol Chem 271:29483-29488, 1996
155. Van Belle E, Witzenbichler B, Chen D, et al: Potentiated angiogenic effect of scatter factor/hepatocyte growth factor via induction of vascular endothelial growth factor: The case for paracrine amplification of angiogenesis. Circulation 97:381-390, 1998
156. Kotsuji-Maruyama T, Imakado S, Kawachi Y, et al: PDGF-BB induces MAP kinase phosphorylation and VEGF expression in neurofibroma-derived cultured cells from patients with neurofibromatosis 1. J Dermatol 29:713-717, 2002
157. Cao R, Brakenhielm E, Li X, et al: Angiogenesis stimulated by PDGF-CC, a novel member in the PDGF family, involves activation of PDGFR-alphaalpha and -alphabeta receptors. FASEB J 16:1575-1583, 2002
158. Guo P, Fang Q, Tao HQ, et al: Overexpression of vascular endothelial growth factor by MCF-7 breast cancer cells promotes estrogen-independent tumor growth in vivo. Cancer Res 63:4684-4691, 2003
159. Reinmuth N, Liu W, Jung YD, et al: Induction of VEGF in perivascular cells defines a potential paracrine mechanism for endothelial cell survival. FASEB J 15:1239-1241, 2001
160. Dong J, Grunstein J, Tajada M, et al: VEGF-null cells require PDGFR α signaling-mediated stromal fibroblast recruitment for tumorigenesis. EMBO J 23:2800-2810, 2004
161. Gately S: The contributions of cyclooxygenase-2 to tumor angiogenesis. Cancer Metastasis Rev 19:19-27, 2000
162. Needleman P, Turk J, Jakschik BA, et al: Arachidonic acid metabolism. Annu Rev Biochem 55:69-102, 1986
163. Joo YE, Rew JS, Seo YH, et al: Cyclooxygenase-2 overexpression correlates with vascular endothelial growth factor expression and tumor angiogenesis in gastric cancer. J Clin Gastroenterol 37:28-33, 2003
164. Yao M, Kargman S, Lam EC, et al: Inhibition of cyclooxygenase-2 by rofecoxib attenuates the growth and metastatic potential of colorectal carcinoma in mice. Cancer Res 63:586-592, 2003
165. Tsujii M, Kawano S, Tsuji S, et al: Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 93:705-716, 1998
166. Liu XH, Kirschenbaum A, Yao S, et al: Upregulation of vascular endothelial growth factor by cobalt chloride-simulated hypoxia is mediated by persistent induction of cyclooxygenase-2 in a metastatic human prostate cancer cell line. Clin Exp Metastasis 17:687-694, 1999
167. Costa C, Soares R, Reis-Filho JS, et al: Cyclo-oxygenase 2 expression is associated with angiogenesis and lymph node metastasis in human breast cancer. J Clin Pathol 55:429-434, 2002
168. Aoki T, Nagakawa Y, Tsuchida A, et al: Expression of cyclooxygenase-2 and vascular endothelial growth factor in pancreatic tumors. Oncol Rep 9:761-765, 2002
169. Eibl G, Bruemmer D, Okada Y, et al: PGE(2) is generated by specific COX-2 activity and increases VEGF production m COX-2-expressing human pancreatic cancer cells. Biochem Biophys Res Commun 306:887-897, 2003
170. Rak J, Mitsuhashi Y, Sheehan C, et al: Oncogenes and tumor angiogenesis: Differential modes of vascular endothelial growth factor up-regulation in ras-transformed epithelial cells and fibroblasts. Cancer Res 60:490-498, 2000
171. Rak J, Yu JL, Kerbel RS, et al: What do oncogenic mutations have to do with angiogenesis/vascular dependence of tumors. Cancer Res 62:1931-1934, 2002
172. Ellis LM, Staley CA, Liu W, et al: Down-regulation of vascular endothelial growth factor in a human colon carcinoma cell line transfected with an antisense expression vector specific for c-src. J Biol Chem 273:1052-1057, 1998
173. Fleming RY, Ellis LM, Parikh NU, et al: Regulation of vascular endothelial growth factor expression in human colon carcinoma cells by activity of src kinase. Surgery 122:501-507, 1997
174. Dias S, Hattori K, Heissig B, et al: Inhibition of both paracrine and autocrine VEGF/VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias. Proc Natl Acad Sci U S A 98:10857-10862, 2001
175. Ebos JM, Tran J, Master Z, et al: Imatinib mesylate (STI-571) reduces Bcr-Abl-mediated vascular endothelial growth factor secretion in chronic myelogenous leukemia. Mol Cancer Res 1:89-95, 2002
176. Konishi T, Huang CL, Adachi M, et al: The K-ras gene regulates vascular endothelial growth factor gene expression in non-small cell lung cancers. Int J Oncol 16:501-511, 2000
177. Ikeda N, Nakajima Y, Sho M, et al: The association of K-ras gene mutation and vascular endothelial growth factor gene expression in pancreatic carcinoma. Cancer 92:488-499, 2001
178. Rak J, Kerbel RS: Ras regulation of vascular endothelial growth factor and angiogenesis. Methods Enzymol 333:267-283, 2001
179. Feldkamp MM, Lau N, Rak J, et al: Normoxic and hypoxic regulation of vascular endothelial growth factor (VEGF) by astrocytoma cells is mediated by Ras. Int J Cancer 81:118-124, 1999
180. Okada F, Rak JW, Croix BS, et al: Impact of oncogenes in tumor angiogenesis: Mutant K-ras up-regulation of vascular endothelial growth factor/vascular permeability factor is necessary, but not sufficient for tumorigenicity of human colorectal carcinoma cells. Proc Natl Acad Sci U S A 95:3609-3614, 1998
181. Zhang X, Gaspard JP, Chung DC: Regulation of vascular endothelial growth factor by the Wnt and K-ras pathways in colonic neoplasia. Cancer Res 61:6050-6054, 2001
182. Rak J, Mitsuhashi Y, Bayko L, et al: Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res 55:4575-4580, 1995
183. Maity A, Pore N, Lee J, et al: Epidermal growth factor receptor transcriptionally up-regulates vascular endothelial growth factor expression in human glioblastoma cells via a pathway involving phosphatidylinositol 3′-kinase and distinct from that induced by hypoxia. Cancer Res 60:5879-5886, 2000
184. Casanova ML, Larcher F, Casanova B, et al: A critical role for ras-mediated, epidermal growth factor receptor-dependent angiogenesis in mouse skin carcinogenesis. Cancer Res 62:3402-3407, 2002
185. Pal S, Datta K, Mukhopadhyay D: Central role of p53 on regulation of vascular permeability factor/vascular endothelial growth factor (VPF/ VEGF) expression in mammary carcinoma. Cancer Res 61:6952-6957, 2001
186. Fujisawa T, Watanabe J, Kamata Y, et al: Effect of p53 gene transfection on vascular endothelial growth factor expression in endometrial cancer cells. Exp Mol Pathol 74:276-281, 2003
187. Bouvet M, Ellis LM, Nishizaki M, et al: Adenovirus-mediated wild-type p53 gene transfer down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human colon cancer. Cancer Res 58:2288-2292, 1998
188. Zundel W, Schindler C, Haas-Kogan D, et al: Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev 14:391-396, 2000
189. Bellamy WT, Richter L, Frutiger Y, et al: Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Res 59:728-733, 1999
190. Decaussin M, Sartelet H, Robert C, et al: Expression of vascular endothelial growth factor (VEGF) and its two receptors (VEGF-R1-Flt1 and VEGF-R2-Flk1/KDR) in non-small cell lung carcinomas (NSCLCs): Correlation with angiogenesis and survival. J Pathol 188:369-377, 1999
191. Dias S, Hattori K, Zhu Z, et al: Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration. J Clin Invest 106:511-521, 2000
192. Ferrer FA, Miller LJ, Lindquist R, et al: Expression of vascular endothelial growth factor receptors in human prostate cancer. Urology 54:567-572, 1999
193. Hayashibara T, Yamada Y, Miyanishi T, et al: Vascular endothelial growth factor and cellular chemotaxis: A possible autocrine pathway in adult T-cell leukemia cell invasion. Clin Cancer Res 7:2719-2726, 2001
194. Lacal PM, Failla CM, Pagani E, et al: Human melanoma cells secrete and respond to placenta growth factor and vascular endothelial growth factor. J Invest Dermatol 115:1000-1007, 2000
195. Price DJ, Miralem T, Jiang S, et al: Role of vascular endothelial growth factor in the stimulation of cellular invasion and signaling of breast cancer cells. Cell Growth Differ 12:129-135, 2001
196. Wu Y, Zhong Z, Li H, et al: A fully human monoclonal antibody against VEGFR-1 inhibits growth of human breast cancers. Proc Am Assoc Cancer Res 45:3005, 2004
197. Fan F, Wey JS, McCarty MF, et al: Expression and function of vascular endothelial growth factor receptor 1 on human colorectal cancer cells. Oncogene: in press
198. Ellis LM, Liu W, Wilson M: Down-regulation of vascular endothelial growth factor in human colon carcinoma cell lines by antisense transfection decreases endothelial cell proliferation. Surgery 120:871-878, 1996
199. Ellis LM, Liu W, Fan F, et al: Role of angiogenesis inhibitors in cancer treatment-Oncology (Huntingt) 15:39-46, 2001
200. Kim KJ, Li B, Winer J, et al: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature 362:841-844, 1993
201. Prewett M, Huber J, Li Y, et al: Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res 59:5209-5218, 1999
202. Gerber HP, Kowalski J, Sherman D, et al: Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor. Cancer Res 60:6253-6258, 2000
203. Klohs WD, Hamby JM: Antiangiogenic agents. Curr Opin Biotechnol 10:544-549, 1999
204. Bruns CJ, Shrader M, Harbison MT, et al: Effect of the vascular endothelial growth factor receptor-2 antibody DC101 plus gemcitabine on growth, metastasis, and angiogenesis of human pancreatic cancer growing orthotopically in nude mice. Int J Cancer 102:101-108, 2002
205. Zhu Z, Lu D, Kotanides H, et al: Inhibition of vascular endothelial growth factor induced mitogenesis of human endothelial cells by a chimeric anti-kinase insert domain-containing receptor antibody. Cancer Lett 136:203-213, 1999
206. Shaheen RM, Ahmad SA, Liu W, et al: Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors. Br J Cancer 85:584-589, 2001
207. Shaheen RM, Tseng WW, Vellagas R, et al: Effects of an antibody to vascular endothelial growth factor receptor-2 on survival, tumor vascularity, and apoptosis in a murine model of colon carcinomatosis. Int J Oncol 18:221-226, 2001
208. Kerbel RS, Yu J, Tran J, et al: Possible mechanisms of acquired resistance to antiangiogenic drugs: Implications for the use of combination therapy approaches. Cancer Metastasis Rev 20:79-86, 2001
209. Kerbel RS: Clinical trials of antiangiogenic drugs: opportunities, problems, and assessment of initial results. J Clin Oncol 19:45s-51s, 2001 (suppl 18)
210. Klement G, Baruchel S, Rak J, et al: Continous low-does therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 105:R15-R24, 2000
211. Huang J, Soffer S, Kim E, et al: Vascular remodeling marks tumor that recur during chronic suppression of angiogenesis. Mol Cancer Res 2:36-42, 2004
212. Korn EL, Arbuck SG, Pluda JM, et al: Clinical trial designs for cytostatic agents: Are new approaches needed? J Clin Oncol 19:265-272, 2001
213. Pluda JM: Tumor-associated angiogenesis: Mechanisms, clinical implications, and therapeutic strategies. Semin Oncol 24:203-218, 1997
214. Kim ES, Serur A, Huang J, et al: Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma. Proc Natl Acad Sci U S A 99:11399-11404, 2002
215. Wood JM, Bold G, Buchdunger E, et al: PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 60:2178-2189, 2000
216. Cobleigh MA, Langmuir VK, Sledge GW, et al: A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol 30:117-124, 2003 (5 suppl 16)
217. Miller K, Rugo HS, Cobleigh MA, et al: Phase III trial of capecitabine (Xeloda) plus bevacizumab (Avastin) versus capecitabine alone in women with metastatic breast cancer previously treated with an anthracycline and a taxane. Breast Cancer Res Treat 76:537, 2002 (suppl 1)
218. Yang JC, Haworth L, Sherry RM, et al: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349:427-434, 2003
219. Hurwitz H, Fehrenbacher L, Cartwright T, et al: Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first-line colorectal cancer (CRC): Results of a phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5-fluorouracil, leucovorin) as first-line therapy in subjects with metastatic CRC. Proc Am Soc Clin Oncol 22:2003 (abstr 3646)
220. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792, 2001
221. Ellis LM, Hoff PM: Targeting the epidermal growth factor receptor: An important incremental step in the battle against colorectal cancer. J Clin Oncol 22:1177-1179, 2004
222. Hess C, Vuong V, Hegyi I, et al: Effect of VEGF receptor inhibitor PTK787 combined with ionizing radiation on endothelial cells and tumour growth. Br J Cancer 85:2010-2016, 2001
223. Hu L, Hofmann J, Zaloudek C, et al: Vascular endothelial growth factor immunoneutralization plus paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer. Am J Pathol 161:1917-1924, 2002
224. Huang J, Frischer JS, Serur A, et al: Regression of established tumors and metastases by potent vascular endothelial growth factor blockade. Proc Natl Acad Sci U S A 100:7785-7790, 2003
225. Inoue K, Slaton JW, Davis DW, et al: Treatment of human metastatic transitional cell carcinoma of the bladder in a murine model with the anti-vascular endothelial growth factor receptor monoclonal antibody DC101 and paclitaxel. Clin Cancer Res 6:2635-2643, 2000
226. Jain RK: Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy. Nat Med 7:987-989, 2001
227. Kozin SV, Boucher Y, Hicklin DJ, et al: Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts. Cancer Res 61:39-44, 2001
228. Lee CG, Heijn M, di Tomaso E, et al: Antivascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res 60:5565-5570, 2000
229. Solorzano CC, Baker CH, Bruns CJ, et al: Inhibition of growth and metastasis of human pancreatic cancer growing in nude mice by PTK 787/ZK222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases. Cancer Biother Radiopharm 16:359-370, 2001
230. Sweeney P, Karashima T, Kim SJ, et al: Anti-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate cancer xenografts via induction of endothelial cell apoptosis and reduction of endothelial cell matrix metalloproteinase type 9 production. Clin Cancer Res 8: 2714-2724, 2002
231. Wild R, Dings RP, Subramanian I, et al: Carboplatin selectively induces the VEGF stress response in endothelial cells: Potentiation of antitumor activity by combination treatment with antibody to VEGF. Int J Cancer 110:343-351, 2004
232. Jain RK: Barriers to drug delivery in solid tumors. Sci Am 271:58-65, 1994
233. Gazit Y, Baish JW, Safabakhsh N, et al: Fractal characteristics of tumor vascular architecture during tumor growth and regression. Microcirculation 4:395-402, 1997
234. Jain RK, Safabakhsh N, Sckell A, et al: Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: role of vascular endothelial growth factor. Proc Natl Acad Sci U S A 95:10820-10825, 1998
235. Willett CG, Boucher Y, di Tomaso E, et al: Direct evidence that the VEGF-specific antibody bevacizumab has anti vascular effects in human rectal cancer. Nat Med 10:145-147, 2004
236. Tong R, Boucher Y, Kozin S, et al: Vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 64:3731-3736, 2004
237. Winkler F, Kozin SV, Di Tomaso E, et al: Normalizing brain tumor vessels with antiangiogenic therapy. Proc Am Assoc Cancer Res 45:2557, 2004
238. Browder T, Butterfield CE, Kraling BM, et al: Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60:1878-1886, 2000
239. Miller KD, Sweeney CJ, Sledge GW, et al: Redefining the target: Chemotherapeutics as antiangiogenics. J Clin Oncol 19:1195-1206, 2001
240. Hanahan D, Bergers G, Bergsland W: Less is more regularly: Metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 105:1045-1047, 2000